Mebeverine

Mebeverine

Clinical data
ATC code	A03AA04 (WHO)
Identifiers
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C25H36NO5
Molar mass	430.5595 g/mol

WikiDoc Resources for Mebeverine
Articles
Most recent articles on Mebeverine Most cited articles on Mebeverine Review articles on Mebeverine Articles on Mebeverine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Mebeverine Images of Mebeverine Photos of Mebeverine Podcasts & MP3s on Mebeverine Videos on Mebeverine
Evidence Based Medicine
Cochrane Collaboration on Mebeverine Bandolier on Mebeverine TRIP on Mebeverine
Clinical Trials
Ongoing Trials on Mebeverine at Clinical Trials.gov Trial results on Mebeverine Clinical Trials on Mebeverine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Mebeverine NICE Guidance on Mebeverine NHS PRODIGY Guidance FDA on Mebeverine CDC on Mebeverine
Books
Books on Mebeverine
News
Mebeverine in the news Be alerted to news on Mebeverine News trends on Mebeverine
Commentary
Blogs on Mebeverine
Definitions
Definitions of Mebeverine
Patient Resources / Community
Patient resources on Mebeverine Discussion groups on Mebeverine Patient Handouts on Mebeverine Directions to Hospitals Treating Mebeverine Risk calculators and risk factors for Mebeverine
Healthcare Provider Resources
Symptoms of Mebeverine Causes & Risk Factors for Mebeverine Diagnostic studies for Mebeverine Treatment of Mebeverine
Continuing Medical Education (CME)
CME Programs on Mebeverine
International
Mebeverine en Espanol Mebeverine en Francais
Business
Mebeverine in the Marketplace Patents on Mebeverine
Experimental / Informatics
List of terms related to Mebeverine

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Mebeverine HCI is a musculotropic antispasmodic drug without atropic side-effects whose major therapeutic role is in the treatment of irritable bowel syndrome. It is also indicated for treatment of gastrointestinal spasm secondary to organic disorder. It was first registered in 1965 and manufacture by Solvay Pharmaceuticals.

Mebeverine HCI presented in tablets (100mg or 135mg), capsules (200mg slow release), and liquid (10mg/ml).

Mode of Action

Mebeverine HCI belongs to a group of compounds called musculotropic antispasmodics. These compounds act directly on the gut muscles at the cellular level to relax them. Mebeverine is also an inhibitor of calcium-depot replenishment. Therefore, mebeverine has dual mode of action which normalizes the small bowel motility.